Stromal Podoplanin Expression as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
Pathobiology · 21.05.2026 · 1-9
DOI: 10.1159/000552666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, online erschienen am 21.05.2026. Verfasst von Betül Öğüt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gazi University, Ankara, Turkey, betulcimer@gazi.edu.tr. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
Pancreatic cancer is known for its poor prognosis, characterized by early systemic dissemination and locally aggressive behavior. Podoplanin (PDPN) is a mucin-type transmembrane glycoprotein physiologically expressed in various tissues. In certain malignancies, overexpression of PDPN has been linked to enhanced tumor invasiveness, metastatic potential, and unfavorable clinical outcomes. In this study, we evaluated stromal PDPN expression in a cohort of patients diagnosed with pancreatic carcinoma and investigated its immunohistochemical profile in relation to patient survival.
Methods
This retrospective study included 103 cases of pancreatic ductal adenocarcinoma (PDAC). Histological grade, perineural invasion, pathological tumor stage, lymph node status, and lymphovascular invasion were evaluated. Immunohistochemical expression of PDPN was evaluated as a percentage by calculating the proportion of PDPN-positive (of any staining intensity) tumor stroma relative to the total tumor stromal area.
Results
Among 103 cases of PDAC, the median value of immunohistochemical expression of PDPN in tumor stroma was 20%. Complete absence of PDPN expression was observed in 7 patients (6.8%). The survival analysis indicated that higher stromal PDPN expression was associated with shorter overall survival (log-rank p = 0.0129). High PDPN expression in cancer-associated fibroblasts showed a borderline association with overall survival in multivariable Cox regression analysis (hazard ratio: 1.52, 95% confidence interval: 1.00–2.32, p = 0.05).
Conclusion
PDPN expression may serve as a prognostic biomarker in PDAC and could contribute to future therapeutic stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Gazi University, Ankara, Turkey, betulcimer@gazi.edu.tr.
- Department of Pathology, Gazi University, Ankara, Turkey.
- Department of Medical Oncology, Gazi University, Ankara, Turkey.
Zitieren
APA
Öğüt, B., İnan, M. A., Ekinci, Ö., Toker, M., Öge, C. B., Sütçüoğlu, O., Gündüz, M. İ., & Akyol, G. (2026). Stromal Podoplanin Expression as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Pathobiology, 1-9. https://doi.org/10.1159/000552666
Vancouver
Öğüt B, İnan MA, Ekinci Ö, Toker M, Öge CB, Sütçüoğlu O, et al. Stromal Podoplanin Expression as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Pathobiology. 2026:1-9. doi:10.1159/000552666
BibTeX
@article{t2026,
author = {Öğüt, Betül and İnan, Mehmet Arda and Ekinci, Özgür and Toker, Meral and Öge, Ceren Bilkan and Sütçüoğlu, Osman and Gündüz, Mualla İlknur and Akyol, Gülen},
title = {Stromal Podoplanin Expression as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma},
journal = {Pathobiology},
year = {2026},
pages = {1--9},
doi = {10.1159/000552666}
}
EUVIMED